Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome

Howard, John M.; Chremos, Athanassios N.; Collen, Martin J.; McArthur, K E; Cherner, Jay A.; Maton, Paul N.; Ciarleglio, Cecelia A.; Cornelius, Mary Jo; Gardner, Jerry D.; Jensen, Robert T.

doi:10.1016/s0016-5085(85)80024-x

Cited by 185 publications

(68 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, it is known that famotidine is 7.5-9 times more potent than ranitidine (19,20). As these reports had discussed the potential efficacy of famotidine and ranitidine on gastric acid secretion, we suggest that famotidine may have a similar more potent action on LES function by an unknown mechanism.…”

Section: Discussionmentioning

confidence: 99%

In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats

Özer

Duman²,

Taş³

et al. 2012

Turk J Gastroenterol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats

Özer

Duman²,

Taş³

et al. 2012

Turk J Gastroenterol

View full text Add to dashboard Cite

“…However, escape phenomena have been observed [8] and resistance to H2-RA has been reported in 10% of the cases [9]. Substituted benzimidazoles (omeprazole and recently lansoprazole) are highly effective in ZES patients (10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Long‐term treatment with octreotide in patients with the Zollinger‐ElIison syndrome

Ruszniewski

Ramdani

Cadiot

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. This study reports the effects of 4 and 5-year treatment with octreotide (200 pg sc bid) in the Zollinger-Ellison syndrome (ZES). No symptoms related to acid hypersecretion were observed in the four patients throughout the study, and upper GI endoscopy was normal. Basal acid output (BAO) measured 12 h after injection, was below 10 mmol h-' in three to four patients and previous ranitidine treatment was discontinued. In the fourth case (pretreatment BAO value: 11 5 mmol h-I), BAO progressively decreased to 42 mmol h-' after 5 years of octreotide treatment. At the end of the study, serum gastrin levels were 58.5% (30-68) of the pretreatment values and two patients had normal gastrin levels. Peak acid output (PAO) decreased markedly after 2,4 and 5 years, by 68% (35-89) suggesting that octreotide had exerted an antitrophic effect on parietal cell mass. Diffuse hyperplasia of fundic argyrophil cells present in two patients before octreotide, decreased during the treatment. Mean argyrophil cell density for all patients was not significantly modified. Antral gastrin-cell density was in the normal range. No long-term side effect of octreotide treatment was observed. Although octreotide may not be considered as a substitute for benzimidazoles in the treatment of ZES, its specific properties may be of therapeutic benefit in some ZES patients.

show abstract

“…Similarly cimetidine has been found to impair the elimination of theophylline in man (Jackson et al, 1980;Roberts et al, 1981). Famotidine, Howard et al, 1985).…”

Section: Introductionmentioning

confidence: 99%

Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.

Lin

Chremos

Chiou

et al. 1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

The comparative effect of famotidine or cimetidine on theophylline disposition was determined in healthy volunteers. Cimetidine, but not famotidine, caused a reduction in the rate of elimination of theophylline. The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min'-during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine. The volume of distribution and renal excretion of theophylline were not affected by either famotidine or cimetidine.

show abstract

Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome

Cited by 185 publications

References 19 publications

In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats

In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats

Long‐term treatment with octreotide in patients with the Zollinger‐ElIison syndrome

Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.

Contact Info

Product

Resources

About